Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

Bibliographic Details
Main Authors: Simonini, Gabriele, Taddio, Andrea, Cattalini, Marco, Caputo, Roberto, de Libero, Cinzia, Parentin, Fulvio, Pagnini, Ilaria, Lepore, Loredana, Cimaz, Rolando
Format: Online
Language:English
Published: BioMed Central 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637103/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637103/

Similar Items